Founded in the UK in 2002, Pharmidex provides high quality experimental preclinical ADMET/PK data, critical to the progression of drug discovery programmes. We have comprehensive in-house laboratory facilities as well as extensive in-vitro and in-vivo assay options. This enables us to provide tailored studies designed to meet individual project needs. Through extensive knowledge of drug discovery and development, Pharmidex has been able to deliver a high level of customer satisfaction and forge several strategic international alliances, focusing on operations in the following areas: in vitro ADMET, in-vivo Pharmacology, CNS Drug Discovery, Bioanalysis, Metabolite Identification, Bioimaging, and Zebrafish.
PhoreMost™ is focused on bringing more effective and affordable targeted medicines to patients. To achieve this aim, PhoreMost is developing a next-generation phenotypic screening technology that can discern the best new targets for future therapy and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases. Based on the company's proprietary Protein Interference (PROTEINi®) technology, PhoreMost has developed SITESEEKER®; a platform that can systematically unmask cryptic druggable sites in the human genome and then link them to useful therapeutic functions in a live-cell context.
Watch our Member Showcase Video https://bit.ly/3rtFquQ
Having been established since 1992, PIA has grown to enjoy a significant reputation by working in partnership with our clients to provide a wide range of specialist insurance products for companies in the Life Science, Bio, Medical Technology and Healthcare sectors.
Being based in the Midlands, we are centrally placed to develop lasting relationships with businesses throughout the UK and Overseas.
Being based in the Midlands, we are centrally placed to develop lasting relationships with businesses throughout the UK and Overseas.
Pioneer Group is a leading force in life sciences and tech, providing cutting-edge lab and office spaces, investment, and expertise to fuel innovation. We support ambitious start-ups, scale-ups, and established firms with world-class facilities, strategic funding, and tailored business guidance.
Our campuses connect scientists, entrepreneurs, and investors, accelerating breakthroughs in health, sustainability, and technology. By fostering collaboration and long-term partnerships, we create dynamic environments where ideas flourish, businesses scale, and industries evolve. Pioneer Group is committed to shaping the future by bridging science and business, driving economic growth, and delivering meaningful impact.
Our campuses connect scientists, entrepreneurs, and investors, accelerating breakthroughs in health, sustainability, and technology. By fostering collaboration and long-term partnerships, we create dynamic environments where ideas flourish, businesses scale, and industries evolve. Pioneer Group is committed to shaping the future by bridging science and business, driving economic growth, and delivering meaningful impact.
No data available
No data available
Prime.io Ltd – We edit genes to accelerate drug discovery
Prime.io is a gene editing contract research organization (CRO) that uses AI-designed gene editing technology and automation to edit genes and accelerate drug discovery. The company is backed by a U.S.-based venture capital firm 50Y as well as Sir Tony Kouzarides.
Cell line engineering services are available in the market but are far from reaching their full potential. Speed, quality, and scalability remain three key challenges facing the drug discovery industry when working with current endogenous gene editing service providers.
The Prime.io team brings over 50 years of combined gene editing experience. Together with a proprietary AI-powered genome editor and automated platform, this enables drug discovery scientists to obtain high-quality endogenous gene-edited clones faster and at scale. This allows drug discovery companies to generate downstream functional cellular validation data more efficiently and make critical decisions faster and with greater confidence.
Prime.io was founded in 2025 by Dr. Rex Li, CEO. The company is based at the London BioScience Innovation Centre (LBIC), 2 Royal College Street, London NW1 0NH.
To learn how we can accelerate your drug discovery research, please contact us:
Website: www.primeio.co.uk
LinkedIn: https://www.linkedin.com/company/108341309
Email: [email protected]
Prime.io is a gene editing contract research organization (CRO) that uses AI-designed gene editing technology and automation to edit genes and accelerate drug discovery. The company is backed by a U.S.-based venture capital firm 50Y as well as Sir Tony Kouzarides.
Cell line engineering services are available in the market but are far from reaching their full potential. Speed, quality, and scalability remain three key challenges facing the drug discovery industry when working with current endogenous gene editing service providers.
The Prime.io team brings over 50 years of combined gene editing experience. Together with a proprietary AI-powered genome editor and automated platform, this enables drug discovery scientists to obtain high-quality endogenous gene-edited clones faster and at scale. This allows drug discovery companies to generate downstream functional cellular validation data more efficiently and make critical decisions faster and with greater confidence.
Prime.io was founded in 2025 by Dr. Rex Li, CEO. The company is based at the London BioScience Innovation Centre (LBIC), 2 Royal College Street, London NW1 0NH.
To learn how we can accelerate your drug discovery research, please contact us:
Website: www.primeio.co.uk
LinkedIn: https://www.linkedin.com/company/108341309
Email: [email protected]
PASM offers clinical trial support services, with special expertise in helping SMEs. Projects undertaken span planning a clinical trials program to meet a regulatory strategy, through to designing and implementing outsourcing strategies to fit the company's needs.
No data available